China has put Illumina on its ‘unreliable entity list’ after the US imposed sanctions on Beijing Genomics Institute, also a ...

Precision Medicine Is the Future Of Healthcare When it comes to applied hard sciences, a source of progress has been more precise measurements and tools. This is especially true in physics and ...

The general mood among these heavyweight investors is divided, with 37% leaning bullish and 37% bearish. Among these notable options, 4 are puts, totaling $366,099, and 4 are calls, amounting to ...

For all of last year, Illumina’s net loss grew 5% from $1.161 billion to $1.223 billion, on revenue that fell 3% from $4.505 ...

ILMN reported fourth-quarter 2024 adjusted earnings per share (EPS) of 86 cents, which missed the Zacks Consensus Estimate of ...

Q4 2024 Earnings Call Transcript February 6, 2025 Illumina, Inc. misses on earnings expectations. Reported EPS is $0.91 EPS, ...

TD Cowen downgraded Illumina (ILMN) to Hold from Buy with a price target of $140, down from $177. Accelerating high throughput next-generation ...

CEO Jacob Thaysen highlighted the transformative progress Illumina made in 2024, emphasizing its strategic roadmap targeting high single-digit revenue growth by 2027. He noted significant advancements ...

Genomics company Illumina (NASDAQ:ILMN) reported Q4 CY2024 results exceeding the market’s revenue expectations, but sales ...

Over the last six months, Angle has overcome technical issues to successfully use Illumina assays, coupled with their next generation sequencing (NGS) platform, to provide a complete solution for the ...